Drug intelligence / Profile preview

ARC103

Development stage: Unknown
Lead developer: Third Arc Bio
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

ARC103 is a bispecific T-cell engager (BiTE) under development by Third Arc Bio. It targets the CD3 molecule on T cells, acting as a stimulant to activate T cell responses. The primary therapeutic area for ARC103 is oncology, with an active indication in stomach cancer and broader potential applications in neoplasms and digestive system disorders. As of June 2025, the drug remains in the discovery phase of development[1].

Other names: ARC103ARC-103ARC 103

Targets

CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on ARC103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARC103.

Explore the full profile